Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in ESLA held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | ARMISTICE CAPITAL, LLC | 4.1M | $4.3M | β | 9.525% | 0.13% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 382K | $405K | β | 0.889% | 0.00% |
| 3 | WELLS FARGO & COMPANY/MN | 264K | $280K | β | 0.614% | 0.00% |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 157K | $167K | +43.4% | 0.366% | 0.00% |
| 5 | VANGUARD FIDUCIARY TRUST CO | 65K | $69K | β | 0.151% | 0.00% |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 63K | $67K | -48.7% | 0.146% | 0.00% |
| 7 | STATE STREET CORP | 43K | $46K | 0.0% | 0.101% | 0.00% |
| 8 | BlackRock, Inc. | 40K | $42K | +50.7% | 0.093% | 0.00% |
| 9 | NORTHERN TRUST CORP | 20K | $21K | 0.0% | 0.046% | 0.00% |
| 10 | US BANCORP \DE\ | 17K | $18K | β | 0.039% | 0.00% |
| 11 | UBS Group AG | 15K | $16K | +373.1% | 0.035% | 0.00% |
| 12 | ROYAL BANK OF CANADA | 7K | $7K | 0.0% | 0.015% | 0.00% |
| 13 | Tower Research Capital LLC (TRC) | 5K | $5K | β | 0.011% | 0.00% |
| 14 | TORONTO DOMINION BANK | 1K | $1K | β | 0.003% | 0.00% |
| 15 | WOLVERINE ASSET MANAGEMENT LLC | 468 | $496 | β | 0.001% | 0.00% |
| 16 | MORGAN STANLEY | 1 | $1 | -100.0% | 0.000% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in ESLA β a direct measure of their conviction.
Filings activity in ESLA during Q1 2026, grouped by how each filer changed its position.
Institutions that opened a new ESLA position in Q1 2026
Institutions that fully closed their ESLA position in Q1 2026
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 16 | +6.7% | 11.70% | +8.38 pp | $5M | +252% |
| Q4 2025 | 15 | +15% | 3.32% | +1.45 pp | $2M | +77% |
| Q3 2025 | 13 | +8.3% | 1.87% | +0.71 pp | $1M | +61% |
| Q2 2025 | 12 | +0.0% | 1.16% | 0.05 pp | $1M | 4.0% |
| Q1 2025 | 12 | +0.0% | 1.21% | +0.48 pp | $1M | +67% |
| Q4 2024 | 12 | +9.1% | 0.73% | +0.24 pp | $0M | +47% |
| Q3 2024 | 11 | +38% | 0.49% | +0.21 pp | $0M | +80% |
| Q2 2024 | 8 | β | 0.28% | β | $0M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying ESLA stock.
Based on Q1 2026 13F filings, institutional ownership of Estrella Immunopharma, Inc. stands at 11.7%, held across 16 reporting institutions.
ARMISTICE CAPITAL, LLC is the largest reported institutional holder of ESLA, with approximately 4,099,000 shares worth $0.00B as of Q1 2026.
Yes β 1 widely-followed marquee investor appear among the top 25 institutional holders of ESLA, including RENAISSANCE TECHNOLOGIES LLC.
Our composite Smart Money Score for ESLA is 60 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
8 institutions opened new positions in ESLA during Q1 2026, while 7 fully exited. 2 added to existing positions and 6 trimmed.
ESLA institutional ownership rose by 8.38 percentage points quarter-over-quarter, with a net change of +1 holders.
The top 10 institutions account for 99.5% of all reported 13F value in ESLA, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Estrella Immunopharma, Inc. (ESLA) Institutional Ownership